Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate: Preliminary findings

Archives of General Psychiatry

Volumn 54, Issue 10, 1997, Pages 953-958

  Nyberg, Svante ^a   Farde, Lars ^a   Halldin, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HALOPERIDOL DECANOATE; RACLOPRIDE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

EID: 0031454363     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830220079011     Document Type: Article

References (28)

1. Gilbert PL, Harris J, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52:173-188.
2. Baldessarini RJ, Vtguera AC. Neuroleptic withdrawal in schizophrenic patients: commentary. Arch Gen Psychiatry. 1995;52:189-191.
3. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
4. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235.
5. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.
6. Baron JC, Martinet JL, Cambon H, Boulenger JP, Poirier MF, Gaillard V, Blin J, Huret JD, Loc'h C, Maziere B. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology. 1989;99:463-472.
7. 2 receptor blockade after depot neuroleptics. J Neural Transm Gen Sect. 1993;94:217-221.
8. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry. 1990;47:213-219.
9. 11C]raclopride in man. Synapse. 1995;20:200-208.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Press; 1987.
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
12. Guy W. Clinical Global Impressions: ECDEU Assessment Manual for Psycho pharmacology. Bethesda, Md: Earty Clinical Drug Evaluation Unit, National Institute Of Health; 1976:218-222.
13. Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L Haloperidol disposition is dependent on debrisoquin hydroxylation phenotype. Ther Drug Monit. 1992;14:92-97.
14. Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;51:12-17.
15. Heim M, Meyer U. Genotyping of poor metabolizers of debrisoquin by allelespectfic PCR amplification. Lancet. 1990;336:529-532.
16. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab. 1989;9:696-708.
17. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O. A comparative PET study of five carbon-11- or fluorine-18-labelled salicylamides: preparation and in vitro dopamine D-2 binding, Int J Radiat Appl Instrum B. 1991;18:871-881.
18. Litton JE, Holte S, Eriksson L. Evaluation of the Karolinska new positron camera system: the Scanditronix PC2048-15B. IEEE Trans Nucl Sci. 1990;37:743-748.
19. Bergstom M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widen L. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr. 1981;5:136-141.
20. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988;45:71-76.
21. 11C]raclopride binding in healthy young adults and schizophrenic patients: reliability and age effects. Hum Psychopharmacol. 1992;7:157-165.
22. Reyntjens AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aerts TJL. Pharmacokinetics of haloperidol decanoate: a 2-year follow-up. Int Pharmacopsychiatry. 1982;17:238-246.
23. Wistedt B, Jorgensen A, Wiles D. A depot neuroleptic withdrawal study: plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology. 1982;78:301-304.
24. Gitlin MJ, Midha K, Fogelson D, Nuechterlein KH. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol. 1988;8:53-56.
25. 2 receptor occupancy: a PET study in haloperidol-treated patients. Psychiatry Res. 1996;67:163-171.
26. Burt D, Creese I, Snyder S. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977;196:326-328.
27. Clow A, Theodorou A, Jenner P, Marsden CD. Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. Eur J Pharmacol. 1980;63:135-144.
28. Owen F, Cross AJ, Waddington JL. Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months' haloperidol administration. Life Sci. 1980;26:55-59.